Sven Mensing
13Patents
7h-index
17Co-inventors
55Inventor score
Filing activity: Sep 4, 2012 → Nov 4, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8466159B2 | Methods for treating HCV | Human Necessities | 24 | Active |
| US8492386B2 | Methods for treating HCV | Physics | 21 | Active |
| US8685984B2 | Methods for treating HCV | Physics | 15 | Active |
| US8809265B2 | Methods for treating HCV | Human Necessities | 15 | Active |
| US8680106B2 | Methods for treating HCV | Human Necessities | 13 | Active |
| US8969357B2 | Methods for treating HCV | Human Necessities | 11 | Active |
| US8993578B2 | Methods for treating HCV | Physics | 11 | Active |
| US8853176B2 | Methods for treating HCV | Human Necessities | 6 | Active |
| US10286029B2 | Method for treating HCV | Human Necessities | 1 | Active |
| US9452194B2 | Methods for treating HCV | Human Necessities | 0 | Active |
| US11285159B2 | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax | Human Necessities | 0 | Active |
| US11484534B2 | Methods for treating HCV | Human Necessities | 0 | Active |
| US8680048B2 | Methods for treating HCV | General | 0 | Revoked |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.